Cosmo Pharmaceuticals N.V.
/ Key word(s): Miscellaneous
GI Genius™ named to FORTUNE 2022 “Change the World” list
Dublin, Ireland – 12 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that Medtronic, its global partner for GI Genius™, published a media release that GI Genius™ intelligent endoscopy module has been named to the prestigious FORTUNE 2022 “Change the World” list.
Today, the GI Genius™ module is the first commercially available computer-aided detection system using AI to help physicians detect polyps and flag signs of colon cancer. The module is poised to have a world-changing impact in the fight against colorectal cancer and improve patient outcomes by assisting physicians in identifying polyps they might otherwise miss, hence the prestigious award.
Alessandro Della Chà, CEO of Cosmo, commented: “It is an absolute honor to have GI Genius™ selected for this prominent recognition. We are excited to see GI Genius™ at the forefront of innovation and making a difference to patients’ lives.”
Please read full details in Medtronic’s press release here.
About Cosmo Pharmaceuticals
|Company:||Cosmo Pharmaceuticals N.V.|
|Riverside 2, Sir John Rogerson’s|
|Dublin 2 Dublin|
|Phone:||+ 353 1 817 0370|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1461219|
|End of News||EQS News Service|